Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy and safety of TQ-B3139 in subjects with ALK-positive non-small cell lung cancer that have demonstrated progression during or after crizotinib treatment whether or not previously treated with cytotoxic chemotherapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04056572
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Li Zhang, Doctor
Phone 020-87343088
Email zhangli@sysucc.org.cn
Status Recruiting
Phase Phase 2
Start date August 13, 2019
Completion date April 30, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05482087 - A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC Phase 2
Active, not recruiting NCT02393625 - Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer Phase 1
Recruiting NCT03804541 - The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human Phase 1
Completed NCT04647110 - Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Recruiting NCT04009317 - Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Phase 3